Bifalgorithm post

This billionaire from Germany discovered a new possible treatment for depression. Now, Big Pharma is paying him $2.8 billion for what he found. His name is Christian Angermeier, a 48-year-old serial entrepreneur and biotech investor who has spent the last decade around breakthrough research. One morning while on a beach, he called a professor of psychopharmacology and asked him about taking mushrooms. The professor said yes, and after a life-altering experience, he thought, "If this helped him, a generally happy and healthy person, imagine what it could do for people suffering from serious depression." The next morning, he flew to New York and set up shop. He co-founded Atai Becley, a biotech-turning psychedelic compounds into FDA-approved medicine, clinically administered and medically supervised during a two-hour treatment window. His scientists developed a nasal spray derived from DMT, designed for treatment-resistant depression. Why does this matter? Depression is a terrible disease with over 300 million people worldwide who suffer from it. Angermeier invested $100 million of his own money into this vision. And this year, Eli Lilly, the company behind Prozac, acquired a Thai Beckley, paying $2.8 billion for control to the research and technology, his 15% stake made him $360 million. The biggest deal in psychedelic medicine history. A mushroom trip on a beach just became what could be a scientific breakthrough for mental health.

This billionaire from Germany discovered a new possible treatment for depression. Now, Big Pharma is paying him $2.8 billion for what he found. His name is Chr…